Posted by Michael Wonder on 27 Mar 2024
Satralizumab for the prevention of relapse in patients with a neuromyelitis optica spectrum disorder
27 March 2024 - NICE is unable to make a recommendation on the use of satralizumab (Enspryng) for the prevention of relapses in adults with a neuromyelitis optica spectrum disorder because Roche did not provide an evidence submission.
NICE will review this decision if Roche decides to make a submission.
